- Home
- TOVX vs BX Comparison
TOVX vs BX Comparison
Compare TOVX & BX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TOVX | BX |
|---|---|---|
| Founded | 2001 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3M | 132.8B |
| IPO Year | 2006 | 2007 |
Fundamental Metrics
Financial Performance| Metric | TOVX | BX |
|---|---|---|
| Price | $0.20 | $152.81 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 15 |
| Target Price | N/A | ★ $180.20 |
| AVG Volume (30 Days) | 2.8M | ★ 4.1M |
| Earning Date | 11-12-2025 | 01-29-2026 |
| Dividend Yield | N/A | ★ 2.61% |
| EPS Growth | N/A | ★ 19.48 |
| EPS | N/A | ★ 3.48 |
| Revenue | N/A | ★ $12,791,218,000.00 |
| Revenue This Year | N/A | $4.00 |
| Revenue Next Year | N/A | $25.64 |
| P/E Ratio | ★ N/A | $43.57 |
| Revenue Growth | N/A | ★ 14.84 |
| 52 Week Low | $0.17 | $115.66 |
| 52 Week High | $2.08 | $190.09 |
Technical Indicators
Market Signals| Indicator | TOVX | BX |
|---|---|---|
| Relative Strength Index (RSI) | 38.79 | 54.95 |
| Support Level | $0.17 | $150.24 |
| Resistance Level | $0.24 | $157.50 |
| Average True Range (ATR) | 0.02 | 3.86 |
| MACD | -0.00 | 0.51 |
| Stochastic Oscillator | 24.56 | 54.69 |
Price Performance
Historical ComparisonAbout TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.
About BX Blackstone Inc.
Blackstone is the world's largest alternative-asset manager with $1.167 trillion in total asset under management, including $860.1 billion in fee-earning assets under management, at the end of March 2025. The company has four core business segments: private equity (26% of fee-earning AUM and 30% of base management fees), real estate (34% and 40%), credit and insurance (32% and 23%), and multi-asset investing (8% and 7%). While the firm primarily serves institutional investors (87% of AUM), it also caters to clients in the high-net-worth channel (13%). Blackstone operates through 25 offices in the Americas (8), Europe and the Middle East (9), and the Asia-Pacific region (8).